Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs DAPT After LAAO (ADALA)
NCT05632445Phase 4
Key facts
- Status
- Completed
- Start
- May 2019
- Primary completion
- Jun 2019
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- apixaban
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 4, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Combined endpoint of death, MI, stroke, thromboembolic complications, major or significant bleeding at 3 months. Started May 2019; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Apixaban
Apixaban for 3 months followed by Aspirin
DAPT
DAPT for 3 months followed by Aspirin
03
Endpoints
Primary
Combined endpoint of death, MI, stroke, thromboembolic complications, major or significant bleeding
Secondary
Combined endpoint of death, MI, stroke, thromboembolic complications, major or significant bleeding at 12 months
Device thrombosis differences between the two strategies
Major bleeding differences between the two strategies
Any bleeding differences between the two strategies
Beyond the preview
Go deeper on NCT05632445.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632445.